TOPICALLY APPLICABLE PHARMACEUTICAL PREPARATION
A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form.
1 - 17 . (canceled)
18 . A topical pharmaceutical preparation comprising an active pharmaceutical ingredient together with one or more pharmaceutical carriers and/or excipients suitable for topical administration, where the active pharmaceutical ingredient is a compound chosen from roflumilast, a salt of roflumilast, the N-oxide of the pyridine residue of roflumilast and a salt thereof, and where one of the pharmaceutical carriers and/or excipients is polyethylene glycol.
19 . A topical pharmaceutical preparation according to claim 18 , where roflumilast is a compound of the formula I
in which
R1 is difluoromethoxy,
R2 is cyclopropylmethoxy and
R3 is 3,5-dichloropyrid-4-yl.
20 . A topical pharmaceutical preparation according to claim 18 , which is a semisolid dosage form chosen from a solution ointment, a suspension ointment, a cream, a gel and a paste.
21 . A topical pharmaceutical preparation according to claim 18 , which is a transdermal therapeutic system (TTS).
22 . A topical pharmaceutical preparation according to claim 18 , characterized in that it is a dosage form for use on the eye.
23 . A topical pharmaceutical preparation according to claim 22 , comprising eye drops.
24 . A topical pharmaceutical preparation according to claim 22 , comprising a suspension of the active pharmaceutical ingredient in the carriers and/or the excipients.
25 . A topical pharmaceutical preparation according to claim 22 , comprising an eye ointment.